<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AZATADINE MALEATE</span><br/>(a-za'ta-deen)<br/><span class="topboxtradename">Optimine, </span><span class="topboxtradename">Trinalin<br/></span><b>Classifications:</b> <span class="classification"> antihistamine (h<sub>1</sub>-receptor antagonist)</span><br/><b>Prototype: </b>Diphenhydramine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Long-acting antihistamine that acts by competitively antagonizing the stimulating effects of histamine at H<sub>1</sub>-receptor sites on smooth muscle of blood vessels and respiratory and GI tract.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The effect is to block or reduce intensity of allergic responses associated with histamine release, such as vasodilation,
         capillary permeability and tissue edema, and itching.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic relief of hay fever (seasonal allergic rhinitis), perennial (or nonseasonal) allergic rhinitis, and chronic urticaria.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to azatadine or to other H<sub>1</sub>-receptor antagonists; <small>MAO INHIBITOR</small> therapy. Safety during pregnancy (category B), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Increased intraocular pressure, narrow-angle glaucoma; pyloroduodenal obstruction, stenosing peptic ulcer; prostatic hypertrophy,
         bladder neck obstruction; hyperthyroidism; hypertension, cardiovascular disease; convulsive disorders; history of asthma or
         COPD.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Allergic Rhinitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 12 mg b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give drug with food or milk to minimize GI adverse effects.</li>
<li>Store at 2°30° C (36°86° F) in tightly closed container, unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness,</span> sedation, dizziness, disturbed coordination, fatigue, confusion, euphoria, excitation, nervousness, restlessness, insomnia,
      tremor, irritability. <span class="typehead"> CV:</span>  Hypotension, palpitation, tachycardia, extrasystoles. <span class="typehead">GI:</span>
<span class="speceff-common">Dry mouth,</span> epigastric distress, nausea, vomiting, anorexia, diarrhea, or constipation. <span class="typehead">Urogenital:</span> Urinary retention, early menses. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Hemolytic anemia</span>, thrombocytopenia, <span class="speceff-life">agranulocytosis</span>. <span class="typehead">Respiratory:</span> Thickening of bronchial secretions. <span class="typehead">Special Senses:</span> Nasal stuffiness; dryness of nose and throat; tinnitus, blurred vision. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>As a general rule, H<sub>1</sub>-receptor antagonists are discontinued about 4 d before <span class="alt">skin testing</span> procedures are to be performed since they may produce false-negative results.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol,</b>
<span class="classification">cns depressants</span> add to sedation, drowsiness; <span class="classification">mao inhibitors</span> may prolong anticholinergic effects of azatadine; <span class="classification">tricyclic antidepressants</span> augment anticholinergic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 4 h. <span class="typehead">Distribution:</span> Probably crosses bloodbrain barrier; crosses placenta; distribution into breast milk unknown. <span class="typehead">Metabolism:</span> Partially metabolized in liver. <span class="typehead">Elimination:</span> 50% excreted in urine in 5 d. <span class="typehead">Half-Life:</span> 912 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for sedation, dizziness, hypotension, and confusion which are more common in older adults. Advise patient to report
            these effects. Reduction in dosage may be indicated.
         </li>
<li>Monitor mental status. There may be additive CNS depression with alcohol and other CNS depressants (e.g., sedatives, tranquilizers,
            sleep medications).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known. This drug commonly causes drowsiness,
            sedation, and dizziness.
         </li>
<li>Avoid concurrent use of alcohol because of potential for additive CNS depression.</li>
<li>Avoid prolonged exposure to sunlight or to artificial ultraviolet light. Photosensitivity is a possible adverse effect.</li>
<li>Relieve dry mouth with frequent rinses with tepid water. Avoid mouthwashes, which contain alcohol that enhances drying.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>